Exact Imaging is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies for prostate cancer.
Trending at Lumira Ventures
Fusion Pharmaceuticals is a clinical-stage bio-pharmaceutical company developing next-generation radio-pharmaceuticals as precision medicines for the treatment of cancer.
G1 Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of novel small-molecule therapies to address significant unmet needs in oncology.
GenEp is a biotechnology company developing therapies that address unmet needs in patients with epilepsy.
HistoSonics is a private medical device company whose mission is to redefine cancer treatment with a non-invasive, highly precise, cost-effective method of tumor destruction call Robotically Assisted Sonic Therapy (RAST™), based on the science of histotripsy.
IMV is a clinical stage company developing a suite of immunotherapeutics for the treatment of solid tumors and infectious diseases.
Iterion Therapeutics is developing novel cancer therapeutics targeting nuclear β-catenin, a historically “undruggable” oncology target implicated in cell proliferation.
KalGene Inc is a pre-clinical stage company focussed on the development of precision medicine therapeutics to slow the progression of Alzheimer’s disease.
KisoJi Biotechnology is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.
LAVA Medtech Acquisition Corp
LAVA Medtech Acquisition Corp. is a newly incorporated blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses.
Medexus Pharmaceuticals is a leading specialty pharmaceutical company with a strong North American commercial platform. Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics.
Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.
Opsens is a fiber optic sensors manufacturer offering solutions for interventional cardiology Fractional Flow Reserve (FFR) as well as solutions for oil and gas industrial applications.
Based in Montreal, OsteoQC is developing new drug candidates for the treatment of bone-related diseases.
PIC Therapeutics is developing a new generation of therapeutics based on the modulation of RNA translation to improve how we treat cancer.